Marilyn Joy Siegel
Research Subjects
Marilyn Joy Siegel has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Charles Hildebolt
5 shared publicationsBarry A. Siegel
From the Edward Mallinckrodt Institute of Radiology and Alvin J. Siteman Cancer Center, Washington University School of Medicine, 510 S Kingshighway Blvd, St Louis, MO 63110
4 shared publicationsEdward Y. Lee
4 shared publicationsJuan Carlos Ramirez-Giraldo
Siemens Healthineers, Malvern, PA
4 shared publications- Shannon G. Farmakis
Chief of Pediatric Imaging, Mercy Children's Hospital, Physician Shareholder, West County Radiological Group, Inc. 615 S. New Ballas Rd. St. Louis, MO 63141
4 shared publications - Thomas E. Herman
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO, USA
4 shared publications
Latest Publications
- 31 January 2025
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
- Vol. 50 (1) , 73-80
Comparison of Radiation Dose and Image Quality in Pediatric Abdominopelvic Photon-Counting Versus Energy-Integrating Detector CT
Objective: Adoption of abdominal photon counting detector CT (PCD-CT) into clinical pediatric CT practice requires evidence that it provides diagnostic images at acceptable radiation doses. Thus, this study aimed to compare radiation dose and image quality of PCD-CT and conventional energy-integrating detector CT (EID-CT) in pediatric abdominopelvic CT. Materials and Methods: This institutional review board–approved retrospective study included 147 children (median age 8.5 y; 80 boys, 67 girls) who underwent clinically indicated contrast-enhanced abdominopelvic PCD-CT between October 1, 2022 and April 30, 2023 and 147 children (median age 8.5 y; 74 boys, 73 girls) who underwent EID-CT between July 1, 2021 and January 1, 2022. Patients in the 2 groups were matched by age and effective diameter. Radiation dose parameters (CT dose index volume, CTDI vol ; dose length product, DLP; size-specific dose estimate, SSDE) were recorded. In a subset of 25 matched pairs, subjective image quality was assessed on a scale of 1 to 4 (1=highest quality), and liver attenuation, dose-normalized noise, and contrast-to-noise ratio (CNR) were measured. Groups were compared using parametric and/or nonparametric testing. Results: Among the 147 matched pairs, there were no significant differences in sex ( P =0.576), age ( P =0.084), or diameter ( P =0.668). PCD-CT showed significantly lower median CTDI vol , DLP, and SSDE (1.6 mGy, 63.8 mGy-cm, 3.1 mGy) compared with EID-CT (3.7 mGy, 155.3 mGy-cm, 6.0 mGy) ( P< 0.001). In the subset of 25 patients, PCD-CT and EID-CT showed no significant difference in overall image quality for reader 1 (1.0 vs. 1.0, P =0.781) or reader 2 (1.0 vs. 1.0, P =0.817), or artifacts for reader 1 (1.0 vs. 1.0, P =0.688) or reader 2 (1.0 vs. 1.0, P =0.219). After normalizing for radiation dose, image noise was significantly lower with PCD-CT ( P P =0.244) and portal vein ( P =0.079) were comparable to EID-CT. Conclusion: Abdominopelvic PCD-CT in children significantly reduces radiation dose while maintaining subjective image quality, and accounting for dose levels, has the potential to lower image noise and achieve comparable CNR to EID-CT. These data expand understanding of the capabilities of PCD-CT and support its routine use in children.
- 31 January 2025
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
- Vol. 50 (1) , 73-80
Comparison of Radiation Dose and Image Quality in Pediatric Abdominopelvic Photon-Counting Versus Energy-Integrating Detector CT
Objective: Adoption of abdominal photon counting detector CT (PCD-CT) into clinical pediatric CT practice requires evidence that it provides diagnostic images at acceptable radiation doses. Thus, this study aimed to compare radiation dose and image quality of PCD-CT and conventional energy-integrating detector CT (EID-CT) in pediatric abdominopelvic CT. Materials and Methods: This institutional review board–approved retrospective study included 147 children (median age 8.5 y; 80 boys, 67 girls) who underwent clinically indicated contrast-enhanced abdominopelvic PCD-CT between October 1, 2022 and April 30, 2023 and 147 children (median age 8.5 y; 74 boys, 73 girls) who underwent EID-CT between July 1, 2021 and January 1, 2022. Patients in the 2 groups were matched by age and effective diameter. Radiation dose parameters (CT dose index volume, CTDI vol ; dose length product, DLP; size-specific dose estimate, SSDE) were recorded. In a subset of 25 matched pairs, subjective image quality was assessed on a scale of 1 to 4 (1=highest quality), and liver attenuation, dose-normalized noise, and contrast-to-noise ratio (CNR) were measured. Groups were compared using parametric and/or nonparametric testing. Results: Among the 147 matched pairs, there were no significant differences in sex ( P =0.576), age ( P =0.084), or diameter ( P =0.668). PCD-CT showed significantly lower median CTDI vol , DLP, and SSDE (1.6 mGy, 63.8 mGy-cm, 3.1 mGy) compared with EID-CT (3.7 mGy, 155.3 mGy-cm, 6.0 mGy) ( P< 0.001). In the subset of 25 patients, PCD-CT and EID-CT showed no significant difference in overall image quality for reader 1 (1.0 vs. 1.0, P =0.781) or reader 2 (1.0 vs. 1.0, P =0.817), or artifacts for reader 1 (1.0 vs. 1.0, P =0.688) or reader 2 (1.0 vs. 1.0, P =0.219). After normalizing for radiation dose, image noise was significantly lower with PCD-CT ( P P =0.244) and portal vein ( P =0.079) were comparable to EID-CT. Conclusion: Abdominopelvic PCD-CT in children significantly reduces radiation dose while maintaining subjective image quality, and accounting for dose levels, has the potential to lower image noise and achieve comparable CNR to EID-CT. These data expand understanding of the capabilities of PCD-CT and support its routine use in children.
- 20 November 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (33) , 3935-3946
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non–Small Cell Lung Cancer
PURPOSE: NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non–small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428 ), a randomized phase II trial, studied whether midtreatment 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can guide individualized/adaptive dose-intensified radiotherapy (RT) to improve and predict outcomes in patients with this disease. MATERIALS AND METHODS: Patients fit for concurrent chemoradiation were randomly assigned (1:2) to standard (60 Gy/30 fractions) or FDG-PET–guided adaptive treatment, stratified by substage, primary tumor size, and histology. All patients had midtreatment FDG-PET/CT; adaptive arm patients had an individualized, intensified boost RT dose to residual metabolically active areas. The primary therapeutic end point was 2-year centrally reviewed freedom from local-regional progression (FFLP), defined as no progression in or near the planning target volume and/or regional nodes. FFLP was analyzed on a modified intent-to-treat population at a one-sided Z -test significance level of 0.15. The primary imaging end point was centrally reviewed change in SUV peak from baseline to midtreatment; its association with FFLP was assessed using the two-sided Wald test on the basis of Cox regression. RESULTS: Of 138 patients enrolled, 127 were eligible. Adaptive-arm patients received a mean 71 Gy in 30 fractions, with mean lung dose 17.9 Gy. There was no significant difference in centrally reviewed 2-year FFLP (59.5% and 54.6% in standard and adaptive arms; P = .66). There were no significant differences in protocol-specified grade 3 toxicities, survival, or progression-free survival ( P > .4). Median SUV peak and metabolic tumor volume (MTV) in the adaptive arm decreased 49% and 54%, from pre-RT to mid-RT PET. However, ΔSUV peak and ΔMTV were not associated with FFLP (hazard ratios, 0.997; P = .395 and .461). CONCLUSION: Midtreatment PET-adapted RT dose escalation as given in this study was safe and feasible but did not improve efficacy outcomes.
- 20 November 2024
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (33) , 3935-3946
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non–Small Cell Lung Cancer
PURPOSE: NRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non–small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428 ), a randomized phase II trial, studied whether midtreatment 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) can guide individualized/adaptive dose-intensified radiotherapy (RT) to improve and predict outcomes in patients with this disease. MATERIALS AND METHODS: Patients fit for concurrent chemoradiation were randomly assigned (1:2) to standard (60 Gy/30 fractions) or FDG-PET–guided adaptive treatment, stratified by substage, primary tumor size, and histology. All patients had midtreatment FDG-PET/CT; adaptive arm patients had an individualized, intensified boost RT dose to residual metabolically active areas. The primary therapeutic end point was 2-year centrally reviewed freedom from local-regional progression (FFLP), defined as no progression in or near the planning target volume and/or regional nodes. FFLP was analyzed on a modified intent-to-treat population at a one-sided Z -test significance level of 0.15. The primary imaging end point was centrally reviewed change in SUV peak from baseline to midtreatment; its association with FFLP was assessed using the two-sided Wald test on the basis of Cox regression. RESULTS: Of 138 patients enrolled, 127 were eligible. Adaptive-arm patients received a mean 71 Gy in 30 fractions, with mean lung dose 17.9 Gy. There was no significant difference in centrally reviewed 2-year FFLP (59.5% and 54.6% in standard and adaptive arms; P = .66). There were no significant differences in protocol-specified grade 3 toxicities, survival, or progression-free survival ( P > .4). Median SUV peak and metabolic tumor volume (MTV) in the adaptive arm decreased 49% and 54%, from pre-RT to mid-RT PET. However, ΔSUV peak and ΔMTV were not associated with FFLP (hazard ratios, 0.997; P = .395 and .461). CONCLUSION: Midtreatment PET-adapted RT dose escalation as given in this study was safe and feasible but did not improve efficacy outcomes.
- 1 September 2024
- Published by Springer Nature
- p. 203-220
Pediatric Abdominal Tumors: Neuroblastoma
- Open Access
- 4 May 2024
- Published by Oxford University Press (OUP) in Radiology Advances
- Vol. 1 (2)
Photon counting detector computed tomography in pediatric cardiothoracic CT imaging
Photon-counting detector computed tomography (PCD-CT) is the most recent advancement in CT technology and has the potential to change clinical practice. Unlike conventional energy-integrated-detector (EID) that uses a two-step process to convert X-rays into a digital signal, PCD-CT directly converts photon energies into electronic signal. The advantages of PCD-CT over EID-CT are higher spatial resolution, electronic noise reduction, higher contrast-to-noise ratio, improved radiation dose efficiency, and intrinsic spectral imaging. Successful implementation into clinical practice requires adaptations in CT protocols. In this review, we summarize the basic principles of PCD-CT and technical scanning factors followed by a discussion of its clinical benefits in pediatric pulmonary and cardiovascular imaging.
- 4 May 2024
- Published by Oxford University Press (OUP) in Radiology Advances
- Vol. 1 (2)
Open AccessPhoton counting detector computed tomography in pediatric cardiothoracic CT imaging
Photon-counting detector computed tomography (PCD-CT) is the most recent advancement in CT technology and has the potential to change clinical practice. Unlike conventional energy-integrated-detector (EID) that uses a two-step process to convert X-rays into a digital signal, PCD-CT directly converts photon energies into electronic signal. The advantages of PCD-CT over EID-CT are higher spatial resolution, electronic noise reduction, higher contrast-to-noise ratio, improved radiation dose efficiency, and intrinsic spectral imaging. Successful implementation into clinical practice requires adaptations in CT protocols. In this review, we summarize the basic principles of PCD-CT and technical scanning factors followed by a discussion of its clinical benefits in pediatric pulmonary and cardiovascular imaging.
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 311 (2) , e231741
Multi-institutional Protocol Guidance for Pediatric Photon-counting CT
This article addresses clinical challenges of photon-counting detector (PCD) CT in pediatric patients by outlining fundamental terminology, explaining technical aspects, and providing protocol guidance for the first commercially available PCD CT scanner.
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 311 (2) , e231741
Multi-institutional Protocol Guidance for Pediatric Photon-counting CT
This article addresses clinical challenges of photon-counting detector (PCD) CT in pediatric patients by outlining fundamental terminology, explaining technical aspects, and providing protocol guidance for the first commercially available PCD CT scanner.
- 1 September 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 5 (5) , e230001
Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations
Purpose To analyze the frequency of discrepant interpretations of progressive disease (PD) between routine clinical and formal Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 interpretations in patients enrolled in solid tumor clinical trials and investigate the causes of discordance. Materials and Methods This retrospective study included patients in solid tumor clinical trials undergoing imaging response assessments based on RECIST 1.1 from January to July 2021. Routine clinical interpretations (RCIs) performed as part of standard workflow and not requiring formal use of any established response criteria were compared with separate local core laboratory interpretations (CLIs) by specially trained radiologists who used software that tracks target lesion measurements, changes in nontarget lesions, and appearance of new lesions longitudinally. The comparison focused on discordant interpretations of PD. Results Among 1053 patients who had both RCIs and CLIs performed, PD was diagnosed on one or both reads in 327 patients (median age, 63.6 [range, 22.4-83.2] years; 57.8% female patients). The RCIs and CLIs agreed with PD status in 65% (213 of 327) of assessments. In 32% (105 of 327) of assessments, RCIs overdiagnosed PD when CLIs diagnosed stable disease, and in 3% (nine of 327), CLIs diagnosed PD when RCIs diagnosed stable disease. Reasons for discrepant RCIs of PD included erroneous target lesion measurements (58%, 61 of 105), erroneous diagnosis of nontarget progression (30%, 32 of 105), and misclassification of new lesions as cancer (11%, 12 of 105). Most patients (93%, 98 of 105) with RCI overdiagnosis of PD remained in the clinical trial for one or more treatment cycles. Conclusion PD was frequently overdiagnosed on RCIs versus formal RECIST 1.1 CLIs which could result in patients removed from the clinical trial inappropriately. Keywords: Oncology, Cancer, Tumor Response, MR Imaging, CT © RSNA, 2023 See also commentary by Margolis and Ruchalski in this issue.
- 1 September 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 5 (5) , e230001
Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations
Purpose To analyze the frequency of discrepant interpretations of progressive disease (PD) between routine clinical and formal Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 interpretations in patients enrolled in solid tumor clinical trials and investigate the causes of discordance. Materials and Methods This retrospective study included patients in solid tumor clinical trials undergoing imaging response assessments based on RECIST 1.1 from January to July 2021. Routine clinical interpretations (RCIs) performed as part of standard workflow and not requiring formal use of any established response criteria were compared with separate local core laboratory interpretations (CLIs) by specially trained radiologists who used software that tracks target lesion measurements, changes in nontarget lesions, and appearance of new lesions longitudinally. The comparison focused on discordant interpretations of PD. Results Among 1053 patients who had both RCIs and CLIs performed, PD was diagnosed on one or both reads in 327 patients (median age, 63.6 [range, 22.4-83.2] years; 57.8% female patients). The RCIs and CLIs agreed with PD status in 65% (213 of 327) of assessments. In 32% (105 of 327) of assessments, RCIs overdiagnosed PD when CLIs diagnosed stable disease, and in 3% (nine of 327), CLIs diagnosed PD when RCIs diagnosed stable disease. Reasons for discrepant RCIs of PD included erroneous target lesion measurements (58%, 61 of 105), erroneous diagnosis of nontarget progression (30%, 32 of 105), and misclassification of new lesions as cancer (11%, 12 of 105). Most patients (93%, 98 of 105) with RCI overdiagnosis of PD remained in the clinical trial for one or more treatment cycles. Conclusion PD was frequently overdiagnosed on RCIs versus formal RECIST 1.1 CLIs which could result in patients removed from the clinical trial inappropriately. Keywords: Oncology, Cancer, Tumor Response, MR Imaging, CT © RSNA, 2023 See also commentary by Margolis and Ruchalski in this issue.
- 1 January 2022
- Published by Springer Nature
- p. 1-18
Pediatric Abdominal Tumors: Neuroblastoma
- 9 November 2021
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
- Vol. 46 (1) , 64-70
Comparison of 100-Kilovoltage Tin Filtration With Advanced Modeled Iterative Reconstruction Protocol to an Automated Kilovoltage Selection With Filtered Back Projection Protocol on Radiation Dose and Image Quality in Pediatric Noncontrast-Enhanced Chest Computed Tomography
Objective: The aim of the study was to compare effects of a 100-kilovoltage (kVp) tin filtration (Sn100kVp) with Advanced Modeled Iterative Reconstruction (ADMIRE) protocol to an automated kVp selection and filtered back projection (FBP) protocol on radiation dose and image quality of in noncontrast-enhanced pediatric chest computed tomography (CT). Methods: This retrospective study included 55 children (12 ± 6 years) undergoing baseline imaging using automated kVp selection with FBP on a second-generation dual-source CT scanner and follow-up CT using Sn100kVp with ADMIRE on a third-generation dual-source CT scanner. The volume CT dose index, dose length product, size-specific dose estimate, and milliamperage were compared. Image quality was calculated using signal-to-noise ratio and subjectively evaluated by 2 radiologists. Results: Mean volume CT dose index, dose length product, and size-specific dose estimate were lower for the Sn100kVp protocol with ADMIRE (0.83 ± 0.18 mGy, 21.9 ± 7.5 mGy × cm, 1.28 ± 0.24 mGy) compared with the automated kVp protocol with FBP (2.17 ± 1.10 mGy, 65.1 ± 41.1 mGy × cm, 3.25 ± 1.44 mGy, P < 0.001), whereas milliamperage was and subjective image quality were higher for Sn100kVp (P < 0.001). Conclusions: A Sn100kVp protocol with ADMIRE lowers dose while maintaining image quality in noncontrast-enhanced pediatric chest CT.
- 9 November 2021
- Published by Wolters Kluwer Health in Journal of Computer Assisted Tomography
- Vol. 46 (1) , 64-70
Comparison of 100-Kilovoltage Tin Filtration With Advanced Modeled Iterative Reconstruction Protocol to an Automated Kilovoltage Selection With Filtered Back Projection Protocol on Radiation Dose and Image Quality in Pediatric Noncontrast-Enhanced Chest Computed Tomography
Objective: The aim of the study was to compare effects of a 100-kilovoltage (kVp) tin filtration (Sn100kVp) with Advanced Modeled Iterative Reconstruction (ADMIRE) protocol to an automated kVp selection and filtered back projection (FBP) protocol on radiation dose and image quality of in noncontrast-enhanced pediatric chest computed tomography (CT). Methods: This retrospective study included 55 children (12 ± 6 years) undergoing baseline imaging using automated kVp selection with FBP on a second-generation dual-source CT scanner and follow-up CT using Sn100kVp with ADMIRE on a third-generation dual-source CT scanner. The volume CT dose index, dose length product, size-specific dose estimate, and milliamperage were compared. Image quality was calculated using signal-to-noise ratio and subjectively evaluated by 2 radiologists. Results: Mean volume CT dose index, dose length product, and size-specific dose estimate were lower for the Sn100kVp protocol with ADMIRE (0.83 ± 0.18 mGy, 21.9 ± 7.5 mGy × cm, 1.28 ± 0.24 mGy) compared with the automated kVp protocol with FBP (2.17 ± 1.10 mGy, 65.1 ± 41.1 mGy × cm, 3.25 ± 1.44 mGy, P < 0.001), whereas milliamperage was and subjective image quality were higher for Sn100kVp (P < 0.001). Conclusions: A Sn100kVp protocol with ADMIRE lowers dose while maintaining image quality in noncontrast-enhanced pediatric chest CT.
- 9 July 2021
- Published by Springer Nature in Pediatric Radiology
- Vol. 51 (11) , 2000-2008
Comparison of radiation dose and image quality between contrast-enhanced single- and dual-energy abdominopelvic computed tomography in children as a function of patient size
Background Widespread adoption of dual-energy computed tomography (DECT) requires evidence it does not cause higher radiation dose than conventional single-energy CT (SECT). While a few publications involving pediatric patients exist, most have focused on small cohorts. Hence, there is still a need for studies that ascertain what radiation doses are expected in larger populations that include representative ranges of patient sizes and ages. Objective To compare radiation dose and image quality of DECT and SECT abdominopelvic examinations in children as a function of patient size. Materials and methods This retrospective study included 860 children (age range: 12.3±5.3 years) who underwent contrast-enhanced abdominopelvic exams on second-generation dual-source CT in a five-year period. Two groups, SECT and DECT, consisting of 430 children each, were matched by 5 effective diameters. Volume CT dose index (CTDIvol) and size-specific dose estimate (SSDE) were analyzed as a function of effective diameter. Objective image quality was compared between the groups. Results DECT SSDEs were lower across all effective patient diameters compared with SECT (mean: 8.5±1.8 mGv vs. 9.3±2.0 mGv, respectively, P≤0.001). DECT CTDIvol was lower compared to SECT (mean: 5.6±2.4 mGv vs. 6.1±2.7 mGv, respectively, P≤0.001) except in the smallest diameter group (0.05). Conclusion In children, regardless of effective diameter, contrast-enhanced abdominopelvic DECT can be performed with a similar or lower dose and similar image quality compared with SECT examinations.
- 9 July 2021
- Published by Springer Nature in Pediatric Radiology
- Vol. 51 (11) , 2000-2008
Comparison of radiation dose and image quality between contrast-enhanced single- and dual-energy abdominopelvic computed tomography in children as a function of patient size
Background Widespread adoption of dual-energy computed tomography (DECT) requires evidence it does not cause higher radiation dose than conventional single-energy CT (SECT). While a few publications involving pediatric patients exist, most have focused on small cohorts. Hence, there is still a need for studies that ascertain what radiation doses are expected in larger populations that include representative ranges of patient sizes and ages. Objective To compare radiation dose and image quality of DECT and SECT abdominopelvic examinations in children as a function of patient size. Materials and methods This retrospective study included 860 children (age range: 12.3±5.3 years) who underwent contrast-enhanced abdominopelvic exams on second-generation dual-source CT in a five-year period. Two groups, SECT and DECT, consisting of 430 children each, were matched by 5 effective diameters. Volume CT dose index (CTDIvol) and size-specific dose estimate (SSDE) were analyzed as a function of effective diameter. Objective image quality was compared between the groups. Results DECT SSDEs were lower across all effective patient diameters compared with SECT (mean: 8.5±1.8 mGv vs. 9.3±2.0 mGv, respectively, P≤0.001). DECT CTDIvol was lower compared to SECT (mean: 5.6±2.4 mGv vs. 6.1±2.7 mGv, respectively, P≤0.001) except in the smallest diameter group (0.05). Conclusion In children, regardless of effective diameter, contrast-enhanced abdominopelvic DECT can be performed with a similar or lower dose and similar image quality compared with SECT examinations.
- 1 January 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 3 (1) , e200097
Dual-Energy CT Material Decomposition in Pediatric Thoracic Oncology
Dual-energy CT has the potential to improve characterization of primary and secondary lesions, evaluation of tumor extent, and assessment of therapy response at a radiation dose that is comparable ... Technical advances in CT have enabled implementation of dual-energy CT into routine clinical practice. By acquiring images at two different energy spectra, dual-energy CT enables material decomposi...
- 1 January 2021
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 3 (1) , e200097
Dual-Energy CT Material Decomposition in Pediatric Thoracic Oncology
Dual-energy CT has the potential to improve characterization of primary and secondary lesions, evaluation of tumor extent, and assessment of therapy response at a radiation dose that is comparable ... Technical advances in CT have enabled implementation of dual-energy CT into routine clinical practice. By acquiring images at two different energy spectra, dual-energy CT enables material decomposi...